US2878264A
(en)
|
|
1959-03-17 |
|
Substituted amino alcohols |
DE1144279B
(de)
|
1957-09-26 |
1963-02-28 |
Robins Co Inc A H |
Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
|
US3135766A
(en)
|
1961-10-03 |
1964-06-02 |
Mead Johnson & Co |
3-substituted-3-pyrrolidinols
|
US3484473A
(en)
|
1967-05-12 |
1969-12-16 |
Buckman Labor Inc |
Methylene bisesters of thiolsulfonic acids
|
DE1934150A1
(de)
|
1968-07-10 |
1970-01-15 |
Pennwalt Corp |
Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US3745162A
(en)
|
1970-08-31 |
1973-07-10 |
Robins Co Inc A H |
1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
|
GB1448437A
(en)
|
1973-02-24 |
1976-09-08 |
Beecham Group Ltd |
Diphenylpropylamines
|
US4022791A
(en)
|
1975-06-03 |
1977-05-10 |
Pfizer Inc. |
2-Aminomethyl-3,4-dihydronaphthalenes
|
GB1504424A
(en)
|
1975-08-09 |
1978-03-22 |
Beecham Group Ltd |
Isoquinoline-derived aminoethers
|
BR7807288A
(pt)
|
1977-11-08 |
1979-06-12 |
Genentech Inc |
Processo para sintese de polinucleotidos
|
DD133885B1
(de)
|
1978-01-04 |
1981-02-25 |
Hans Lehmann |
Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
US4542142A
(en)
|
1982-11-22 |
1985-09-17 |
Roussel Uclaf |
Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
US5118800A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
Oligonucleotides possessing a primary amino group in the terminal nucleotide
|
US5643889A
(en)
*
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
FR2567892B1
(fr)
|
1984-07-19 |
1989-02-17 |
Centre Nat Rech Scient |
Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
FR2576898B1
(fr)
|
1985-02-01 |
1988-01-08 |
Lafon Labor |
Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
|
JPH0658512B2
(ja)
|
1985-04-12 |
1994-08-03 |
富士写真フイルム株式会社 |
ハロゲン化銀写真感光材料
|
US4659774A
(en)
|
1985-11-01 |
1987-04-21 |
American Hoechst Corporation |
Support for solid-phase oligonucleotide synthesis
|
US4735949A
(en)
|
1986-02-18 |
1988-04-05 |
Warner-Lambert Company |
Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
|
US4840956A
(en)
|
1986-02-18 |
1989-06-20 |
Warner-Lambert Company |
Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
|
IL83663A0
(en)
|
1986-10-27 |
1988-01-31 |
Robins Co Inc A H |
Preparation of 3-pyrrolidinols
|
DE3851889T2
(de)
|
1987-06-24 |
1995-04-13 |
Florey Howard Inst |
Nukleosid-derivate.
|
US5200553A
(en)
|
1987-07-30 |
1993-04-06 |
Kupat Holim Health Insurance Institution Of The General Federation Of Labor |
Biologically active carboxylic acid esters
|
US4923901A
(en)
|
1987-09-04 |
1990-05-08 |
Millipore Corporation |
Membranes with bound oligonucleotides and peptides
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
US4943629A
(en)
|
1988-08-12 |
1990-07-24 |
American Cyanamid Company |
Antidiabetic alpha-substituted phosphonates
|
US4945158A
(en)
|
1988-08-12 |
1990-07-31 |
American Cyanamid Company |
Antidiabetic phosphonates
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
JP2794461B2
(ja)
|
1989-08-17 |
1998-09-03 |
有機合成薬品工業株式会社 |
ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
|
US5141813A
(en)
|
1989-08-28 |
1992-08-25 |
Clontech Laboratories, Inc. |
Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
CA2029273A1
(en)
|
1989-12-04 |
1991-06-05 |
Christine L. Brakel |
Modified nucleotide compounds
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
CA2071897A1
(en)
|
1989-12-28 |
1991-06-29 |
Richard A. Glennon |
Sigma receptor ligands and the use thereof
|
CA2073500C
(en)
|
1990-01-11 |
2008-03-25 |
Phillip Dan Cook |
Compositions and methods for detecting and modulating rna activity and gene expression
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5852188A
(en)
*
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
US5620963A
(en)
|
1991-10-15 |
1997-04-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
|
US5635488A
(en)
|
1991-10-15 |
1997-06-03 |
Isis Pharmaceuticals, Inc. |
Compounds having phosphorodithioate linkages of high chiral purity
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
US5506212A
(en)
|
1990-01-11 |
1996-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides with substantially chirally pure phosphorothioate linkages
|
US5457191A
(en)
|
1990-01-11 |
1995-10-10 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5292875A
(en)
|
1990-04-20 |
1994-03-08 |
Lynx Therapeutics, Inc. |
Method of synthesizing sulfurized oligonucleotide analogs
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
HUT63568A
(en)
|
1990-05-23 |
1993-09-28 |
Isis Pharmaceuticals Inc |
Composition and process for controlling the activity of rna by modifying the rna 5' cap structure
|
US6087482A
(en)
|
1990-07-27 |
2000-07-11 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
WO1994022886A1
(en)
|
1993-03-30 |
1994-10-13 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
US5783682A
(en)
|
1990-07-27 |
1998-07-21 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide mimics having nitrogen-containing linkages
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
CA2088258C
(en)
|
1990-07-27 |
2004-09-14 |
Phillip Dan Cook |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
US5834607A
(en)
|
1990-07-27 |
1998-11-10 |
Isis Pharmaceuticals, Inc. |
Amines and methods of making and using the same
|
US5223618A
(en)
|
1990-08-13 |
1993-06-29 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analog compounds
|
US6121433A
(en)
|
1990-07-27 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having nitrogen-containing linkages
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
US5998603A
(en)
|
1994-09-29 |
1999-12-07 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analogs, and oligomers thereof
|
US5792844A
(en)
|
1990-07-27 |
1998-08-11 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent nitrogen atoms
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US20020183502A1
(en)
|
1991-05-21 |
2002-12-05 |
Mesmaeker Alain De |
Backbone-modified oligonucleotide analogs and methods for using same
|
US6414112B1
(en)
|
1991-05-24 |
2002-07-02 |
Ole Buchardt |
Peptide nucleic acids having 2,6-diaminopurine nucleobases
|
UA43310C2
(uk)
|
1991-06-10 |
2001-12-17 |
Лакі Лімітед |
Поліпептид вірусу гепатиту с корейського типу (khcv), кднк khcv, полінуклеотид, що кодує поліпептид khcv, рекомбінантний експресуючий вектор, клітина, трансформована вектором, поліпептид, який містить епітоп, спосіб одержання поліпептиду, діагностичний засіб для визначення антитіла, спрямованого проти антигену khcv, діагностичний набір, діагностичний спосіб визначення антитіла, спрямованого проти антигену khcv, моноклональне антитіло, клітинна лінія, діагностичний засіб для визначення епітопу khcv у зразку, що піддають тестуванню, спосіб визначення епітопу khcv, вакцина для лікування або профілактики інфекції khcv (варіанти), набір для визначення полінуклеотиду khcv, спосіб визначення полінуклеотиду з khcv
|
US5359052A
(en)
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
US5646267A
(en)
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
WO1993008296A1
(en)
|
1991-10-15 |
1993-04-29 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
US5654284A
(en)
|
1991-10-15 |
1997-08-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
EP0538194B1
(de)
|
1991-10-17 |
1997-06-04 |
Novartis AG |
Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
DK1695979T3
(da)
|
1991-12-24 |
2011-10-10 |
Isis Pharmaceuticals Inc |
Gappede modificerede oligonukleotider
|
GB9213601D0
(en)
|
1992-06-26 |
1992-08-12 |
Mastico Robert A |
Protein based delivery system
|
US7067497B2
(en)
|
1992-09-29 |
2006-06-27 |
Isis Pharmaceuticals, Inc. |
Modulation of telomere length by oligonucleotides having a G-core sequence
|
US6005107A
(en)
|
1992-12-23 |
1999-12-21 |
Biochem Pharma, Inc. |
Antiviral compounds
|
US6444656B1
(en)
|
1992-12-23 |
2002-09-03 |
Biochem Pharma, Inc. |
Antiviral phosphonate nucleotides
|
ES2086997T3
(es)
|
1993-01-25 |
1996-07-01 |
Hybridon Inc |
Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
|
WO1994022888A1
(en)
|
1993-03-31 |
1994-10-13 |
Sterlingwinthrop Inc. |
Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
|
AU6449294A
(en)
|
1993-03-31 |
1994-10-24 |
Sterling Winthrop Inc. |
Novel 5'-substituted nucleosides and oligomers produced therefrom
|
US5955591A
(en)
*
|
1993-05-12 |
1999-09-21 |
Imbach; Jean-Louis |
Phosphotriester oligonucleotides, amidites and method of preparation
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
DE69412704T2
(de)
|
1993-06-10 |
1999-02-04 |
Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo |
Spritzgiessform
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US5643989A
(en)
*
|
1993-10-29 |
1997-07-01 |
Azdel, Inc. |
Fiber reinforced functionalized polyolefin composites
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
DE4435728A1
(de)
|
1994-01-19 |
1995-07-20 |
Boehringer Mannheim Gmbh |
Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
CA2183431A1
(en)
|
1994-02-22 |
1995-08-24 |
Allan Svendsen |
A method of preparing a variant of a lipolytic enzyme
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
HUT75368A
(en)
|
1994-05-11 |
1997-05-28 |
Novo Nordisk As |
An enzyme with endo-1,3(4)-beta-glucanase activity
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
DK0685475T3
(da)
|
1994-05-31 |
1999-08-30 |
Bayer Ag |
Amino-benzofuryl- og thienylderivater
|
HRP950288A2
(en)
|
1994-05-31 |
1997-08-31 |
Bayer Ag |
Oxalylamino-benzofuran- and benzothienyl-derivatives
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
ATE420171T1
(de)
|
1994-07-15 |
2009-01-15 |
Univ Iowa Res Found |
Immunomodulatorische oligonukleotide
|
ATE202569T1
(de)
*
|
1994-09-07 |
2001-07-15 |
Hybridon Inc |
Prodrug-oligonukleotide
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
EP0807171A1
(en)
|
1994-12-22 |
1997-11-19 |
HYBRIDON, Inc. |
Synthesis of stereospecific oligonucleotide phosphorothioates
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
WO1996027606A1
(en)
|
1995-03-06 |
1996-09-12 |
Isis Pharmaceuticals, Inc. |
Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
|
EP0739983B1
(en)
|
1995-04-27 |
2009-12-30 |
Takara Bio Inc. |
Gene encoding lacto-n-biosidase
|
MX9708663A
(es)
|
1995-05-11 |
1998-02-28 |
Applied Research Systems |
Inhibidor de actividad il-6.
|
AU5855296A
(en)
|
1995-05-19 |
1996-11-29 |
Glycomed Incorporated |
Collection of activated glycoside compounds and their biolog ical use
|
ATE194990T1
(de)
|
1995-05-23 |
2000-08-15 |
Hybridon Inc |
Synthon für stereoselektive oligonukleotid- synthese
|
AU5871196A
(en)
|
1995-05-23 |
1996-12-24 |
Hybridon, Inc. |
Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
|
JPH10510433A
(ja)
|
1995-06-06 |
1998-10-13 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
|
US5932450A
(en)
|
1995-06-07 |
1999-08-03 |
Gen-Probe Incorporated |
Enzymatic synthesis of oligonucleotides using digestible templates
|
US5795765A
(en)
|
1995-06-29 |
1998-08-18 |
Takara Shuzo Co., Ltd. |
Gene encoding endoglycoceramidase
|
DE69636649T2
(de)
|
1995-06-29 |
2007-10-04 |
Takara Bio Inc., Otsu |
Für einen Endoglycoceramidase-Aktivator kodierendes Gen
|
US6017700A
(en)
|
1995-08-04 |
2000-01-25 |
Bayer Corporation |
Cationic oligonucleotides, and related methods of synthesis and use
|
US5936080A
(en)
|
1996-05-24 |
1999-08-10 |
Genta Incorporated |
Compositions and methods for the synthesis of organophosphorus derivatives
|
WO1997009443A1
(en)
|
1995-09-05 |
1997-03-13 |
Michigan State University |
PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
|
US6160109A
(en)
|
1995-10-20 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Preparation of phosphorothioate and boranophosphate oligomers
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
US6476216B1
(en)
|
1995-10-20 |
2002-11-05 |
Mcgill University |
Preparation of phosphorothioate oligomers
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
US6214805B1
(en)
|
1996-02-15 |
2001-04-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
RNase L activators and antisense oligonucleotides effective to treat RSV infections
|
AU708535B2
(en)
|
1996-02-15 |
1999-08-05 |
Cleveland Clinic Foundation, The |
RNase L activators and antisense oligonucleotides effective to treat RSV infections
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
US5824669A
(en)
|
1996-03-22 |
1998-10-20 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
|
ATE377074T1
(de)
|
1996-05-10 |
2007-11-15 |
Novozymes As |
Methode zur bereitstellung von dna sequenzen
|
US5856465A
(en)
|
1996-05-24 |
1999-01-05 |
Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych |
Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
DE19622783A1
(de)
|
1996-06-07 |
1997-12-11 |
Hoechst Ag |
Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
|
DE69736667T2
(de)
|
1996-07-16 |
2007-09-06 |
Gen-Probe Inc., San Diego |
Verfahren zum nachweis und amplifikation von nukleinsäuresequenzen unter verbrauch von modifizierten oligonukleotiden mit erhöhter zielschmelztemperatur (tm)
|
AU717387B2
(en)
|
1996-07-24 |
2000-03-23 |
Rolf H. Berg |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
WO1998007734A1
(en)
*
|
1996-08-21 |
1998-02-26 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
GB9621522D0
(en)
|
1996-10-16 |
1996-12-04 |
Biocompatibles Ltd |
Synthesis of phosphorus compounds
|
US6639062B2
(en)
|
1997-02-14 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6369237B1
(en)
|
1997-03-07 |
2002-04-09 |
President And Fellows Of Harvard College |
DNA glycosylase inhibitors, and uses related thereto
|
US6015887A
(en)
|
1997-04-11 |
2000-01-18 |
Isis Pharmaceuticals, Inc. |
Chiral peptide nucleic acids and methods for preparing same
|
US6468983B2
(en)
|
1997-04-21 |
2002-10-22 |
The Cleveland Clinic Foundation |
RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
|
PL184612B1
(pl)
|
1997-04-25 |
2002-11-29 |
Pan |
Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
|
NZ501289A
(en)
|
1997-05-28 |
2001-06-29 |
Nielsen Peter E |
Conjugated peptide nucleic acids having enhanced cellular uptake
|
CA2295110A1
(en)
|
1997-06-27 |
1999-01-07 |
The Procter & Gamble Company |
Pro-fragrance cyclic acetals
|
WO1999005160A2
(en)
|
1997-07-25 |
1999-02-04 |
Hybridon, Inc. |
Oligonuclotides having 3' terminal stereospecific phosphorothioates
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
GB9717158D0
(en)
|
1997-08-13 |
1997-10-22 |
King S College London |
Solution synthesis of oligonucleotides and their phosphorothioate analogues
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
US6750344B1
(en)
|
1997-09-05 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Amine compounds and combinatorial libraries comprising same
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
DE19741715A1
(de)
|
1997-09-22 |
1999-03-25 |
Hoechst Ag |
Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
US6528640B1
(en)
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
US6080543A
(en)
|
1997-12-08 |
2000-06-27 |
E. & J. Gallo Winery |
Detection of fungal pathogens
|
US6582936B1
(en)
|
1997-12-12 |
2003-06-24 |
The Regents Of The University Of California |
Methods for making nucleic acids
|
US6248519B1
(en)
|
1998-03-11 |
2001-06-19 |
E & J Gallo Winery |
Detection of fermentation-related microorganisms
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
WO1999056755A1
(en)
|
1998-05-06 |
1999-11-11 |
University Of Iowa Research Foundation |
Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
|
IL139646A0
(en)
|
1998-05-14 |
2002-02-10 |
Coley Pharm Group Inc |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
EP1100807A1
(en)
|
1998-07-27 |
2001-05-23 |
University Of Iowa Research Foundation |
STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
|
US7049302B1
(en)
|
1998-08-10 |
2006-05-23 |
Antigenics Inc. |
Compositions of CPG and saponin adjuvants and uses thereof
|
WO2000023444A1
(en)
|
1998-10-21 |
2000-04-27 |
Abbott Laboratories |
5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
WO2000031110A1
(en)
|
1998-11-25 |
2000-06-02 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
US6451524B1
(en)
|
1998-11-25 |
2002-09-17 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
ATE438724T1
(de)
|
1998-12-21 |
2009-08-15 |
Genencor Int |
Chemisch modifizierte enzymen mit mehrfachgeladenen varianten
|
WO2000040749A2
(en)
|
1999-01-06 |
2000-07-13 |
Genenews Inc. |
Method for the detection of gene transcripts in blood and uses thereof
|
US6265172B1
(en)
|
1999-02-08 |
2001-07-24 |
University Of Kentucky |
Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
US6506594B1
(en)
|
1999-03-19 |
2003-01-14 |
Cornell Res Foundation Inc |
Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
|
GB9907245D0
(en)
|
1999-03-29 |
1999-05-26 |
Goldsborough Andrew |
Cleavage of nucleic acids from solid supports
|
JP3072345B1
(ja)
|
1999-03-31 |
2000-07-31 |
農林水産省家畜衛生試験場長 |
豚丹毒菌の組換えサブユニットワクチン
|
US5998148A
(en)
|
1999-04-08 |
1999-12-07 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microtubule-associated protein 4 expression
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
US6300069B1
(en)
|
1999-05-03 |
2001-10-09 |
Qiagen Gmbh |
Generation and amplification of nucleic acids from ribonucleic acids
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6271004B1
(en)
|
1999-06-25 |
2001-08-07 |
Display Systems Biotech A/S |
Method for improved reverse transcription at high temperatures
|
US6066500A
(en)
|
1999-06-25 |
2000-05-23 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Beta catenin expression
|
US6414135B1
(en)
|
1999-07-07 |
2002-07-02 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate monomers and related compounds
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US7264932B2
(en)
|
1999-09-24 |
2007-09-04 |
Applera Corporation |
Nuclease inhibitor cocktail
|
AP1775A
(en)
|
1999-09-25 |
2007-08-28 |
Univ Iowa Res Found |
Immunostimulatory nucleic acids.
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
DE60029460T3
(de)
|
1999-09-27 |
2011-02-10 |
Coley Pharmaceutical Gmbh |
Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
|
US20020082227A1
(en)
|
1999-09-30 |
2002-06-27 |
Scott Henry |
Use of oligonucleotides for inhibition of complement activation
|
WO2001025488A2
(en)
|
1999-10-06 |
2001-04-12 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger rna
|
GB9924285D0
(en)
|
1999-10-14 |
1999-12-15 |
Avecia Ltd |
Process
|
US20010055761A1
(en)
|
1999-10-29 |
2001-12-27 |
Agilent Technologies |
Small scale dna synthesis using polymeric solid support with functionalized regions
|
FR2800750B1
(fr)
|
1999-11-05 |
2003-01-31 |
Centre Nat Rech Scient |
Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
|
AU1656601A
(en)
|
1999-11-12 |
2001-06-12 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6322985B1
(en)
|
1999-12-27 |
2001-11-27 |
Technion Research And Development Foundation Ltd. |
Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
|
WO2001050117A1
(en)
|
1999-12-30 |
2001-07-12 |
Cabot Corporation |
Sensors with improved properties
|
WO2001050349A1
(en)
|
1999-12-30 |
2001-07-12 |
Rutgers, The State University Of New Jersey |
Electronic document customization and transformation utilizing user feedback
|
US6649750B1
(en)
|
2000-01-05 |
2003-11-18 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotide compounds
|
US6159697A
(en)
|
2000-01-19 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad7 expression
|
US7585847B2
(en)
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
GB0004889D0
(en)
|
2000-03-01 |
2000-04-19 |
Avecia Ltd |
Synthesis of oligonucleotides
|
CA2335389A1
(en)
|
2000-03-01 |
2001-09-01 |
Message Pharmaceuticals, Inc. |
Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
|
WO2001070663A2
(en)
|
2000-03-17 |
2001-09-27 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
AU2001273942B2
(en)
|
2000-04-20 |
2005-09-01 |
F. Hoffmann-La Roche Ag |
Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
|
DE10019756A1
(de)
|
2000-04-20 |
2001-10-25 |
Bayer Ag |
Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
|
US20020013287A1
(en)
*
|
2000-05-09 |
2002-01-31 |
Reliable Biopharmaceuticals, Inc. St Louis Missouri |
Polymeric compounds useful as prodrugs
|
US6492171B2
(en)
|
2000-05-16 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of TERT expression
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
WO2002012263A1
(en)
|
2000-08-03 |
2002-02-14 |
Roche Diagnostics Gmbh |
Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses
|
US6725412B1
(en)
|
2000-08-15 |
2004-04-20 |
Dolby Laboratories Licensing Corporation |
Low latency data encoder
|
US6809195B1
(en)
|
2000-08-16 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotides
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
CA2419894A1
(en)
|
2000-09-15 |
2002-03-21 |
Coley Pharmaceutical Gmbh |
Process for high throughput screening of cpg-based immuno-agonist/antagonist
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
GB0024752D0
(en)
|
2000-10-10 |
2000-11-22 |
Univ Belfast |
Oxidative halogenation of aromatic compounds
|
EP1326638B9
(en)
|
2000-10-18 |
2008-02-20 |
GlaxoSmithKline Biologicals S.A. |
Vaccines against cancers
|
US6372492B1
(en)
|
2000-10-30 |
2002-04-16 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of talin expression
|
US6682889B1
(en)
|
2000-11-08 |
2004-01-27 |
Becton, Dickinson And Company |
Amplification and detection of organisms of the Chlamydiaceae family
|
NL1016978C2
(nl)
|
2000-12-22 |
2002-06-25 |
Robert Jan Colenbrander |
Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
|
SI1355916T1
(sl)
|
2001-01-22 |
2007-04-30 |
Merck & Co Inc |
Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
|
ATE501251T1
(de)
|
2001-01-25 |
2011-03-15 |
Evolva Ltd |
Zellbibliothek
|
US8008459B2
(en)
|
2001-01-25 |
2011-08-30 |
Evolva Sa |
Concatemers of differentially expressed multiple genes
|
NZ526507A
(en)
|
2001-01-26 |
2005-07-29 |
Commw Scient Ind Res Org |
Methods and means for producing efficient silencing construct using recombinational cloning
|
US20050277133A1
(en)
|
2001-05-18 |
2005-12-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20030207804A1
(en)
|
2001-05-25 |
2003-11-06 |
Muthiah Manoharan |
Modified peptide nucleic acids
|
GB0113523D0
(en)
|
2001-06-04 |
2001-07-25 |
Torotrak Dev Ltd |
An Hydraulic control circuit for a continuosly variable transmission
|
US20030069410A1
(en)
|
2001-06-14 |
2003-04-10 |
Isis Pharmaceuticals, Inc. |
Methods for preparing oligonucleotides having chiral phosphorothioate linkages
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
JP4370161B2
(ja)
|
2001-06-29 |
2009-11-25 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
Hcve1e2ワクチン組成物
|
JP2005504020A
(ja)
|
2001-07-03 |
2005-02-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ヌクレアーゼ耐性キメラオリゴヌクレオチド
|
US7205399B1
(en)
|
2001-07-06 |
2007-04-17 |
Sirna Therapeutics, Inc. |
Methods and reagents for oligonucleotide synthesis
|
US6440739B1
(en)
|
2001-07-17 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of glioma-associated oncogene-2 expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US6455308B1
(en)
|
2001-08-01 |
2002-09-24 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of serum amyloid A4 expression
|
US7888324B2
(en)
|
2001-08-01 |
2011-02-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
WO2003020884A2
(en)
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
EP1418877A2
(en)
|
2001-08-24 |
2004-05-19 |
Massachusetts Institute Of Technology |
Reagents that facilitate the purification of compounds synthesized on a solid support
|
US7049122B2
(en)
|
2001-09-21 |
2006-05-23 |
Academia Sinica |
Mutant-type lipases and applications thereof
|
US6933288B2
(en)
|
2002-02-04 |
2005-08-23 |
Isis Pharmaceuticals, Inc. |
Pyranosyl cytosines: pharmaceutical formulations and methods
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
US20040149587A1
(en)
|
2002-02-15 |
2004-08-05 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
US20030159938A1
(en)
|
2002-02-15 |
2003-08-28 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050096284A1
(en)
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US7285658B2
(en)
|
2002-02-28 |
2007-10-23 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
JP2005524662A
(ja)
|
2002-02-28 |
2005-08-18 |
ビオタ インコーポレーティッド |
ヌクレオシド5’−一リン酸模倣物およびこれらのプロドラッグ
|
US7288376B2
(en)
|
2002-03-22 |
2007-10-30 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
|
US20040102394A1
(en)
|
2002-11-23 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of huntingtin interacting protein 2 expression
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
AU2003237875A1
(en)
|
2002-05-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
US20040014108A1
(en)
|
2002-05-24 |
2004-01-22 |
Eldrup Anne B. |
Oligonucleotides having modified nucleoside units
|
US20040014957A1
(en)
|
2002-05-24 |
2004-01-22 |
Anne Eldrup |
Oligonucleotides having modified nucleoside units
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
AU2003248708A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
AU2003242742B2
(en)
|
2002-06-20 |
2009-04-30 |
Cytos Biotechnology Ag |
Packaged virus-like particles for use as adjuvants: method of preparation and use
|
WO2004003228A1
(en)
|
2002-07-01 |
2004-01-08 |
Unisearch Limited |
Genotyping method
|
ES2550609T3
(es)
|
2002-07-10 |
2015-11-11 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Interferencia de ARN mediante de moléculas de ARN de cadena sencilla
|
US20040023905A1
(en)
|
2002-07-31 |
2004-02-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of LAR expression
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20050255086A1
(en)
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
WO2004014312A2
(en)
|
2002-08-08 |
2004-02-19 |
Sirna Therapeutics, Inc. |
Small-mer compositions and methods of use
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
US7414116B2
(en)
|
2002-08-23 |
2008-08-19 |
Illumina Cambridge Limited |
Labelled nucleotides
|
MXPA05002791A
(es)
|
2002-09-13 |
2005-12-05 |
Replicor Inc |
Oligonucleotidos antivirales complementarios sin secuencia.
|
US7030230B2
(en)
|
2002-10-25 |
2006-04-18 |
Isis Pharmaceuticals, Inc. |
Process of purifying phosphoramidites
|
EP1556077A2
(en)
|
2002-10-29 |
2005-07-27 |
Coley Pharmaceutical Group, Ltd |
Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
|
US20040147020A1
(en)
|
2002-11-01 |
2004-07-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Dopamine neurons from human embryonic stem cells
|
US7696345B2
(en)
|
2002-11-05 |
2010-04-13 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
AU2003291721A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
WO2004044139A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
WO2004044141A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Conjugated oligomeric compounds and their use in gene modulation
|
US7381527B2
(en)
|
2002-11-06 |
2008-06-03 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants
|
EP2336318B1
(en)
|
2002-11-13 |
2013-04-24 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
JP2006507841A
(ja)
|
2002-11-14 |
2006-03-09 |
ダーマコン, インコーポレイテッド |
機能的siRNAおよび超機能的siRNA
|
WO2004080466A1
(en)
|
2003-03-07 |
2004-09-23 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
GB0306657D0
(en)
|
2003-03-24 |
2003-04-30 |
Avecia Ltd |
Process and compounds
|
BRPI0408623A
(pt)
|
2003-03-26 |
2006-03-07 |
Cytos Biotechnology Ag |
conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
AU2004233989A1
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
WO2004096233A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
US20090247488A1
(en)
|
2003-04-25 |
2009-10-01 |
Carina Cannizzaro |
Anti-inflammatory phosphonate compounds
|
ATE490788T1
(de)
|
2003-04-25 |
2010-12-15 |
Gilead Sciences Inc |
Antivirale phosphonate analoge
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
CN101410120A
(zh)
|
2003-04-25 |
2009-04-15 |
吉里德科学公司 |
抗炎的膦酸酯化合物
|
US7045306B2
(en)
|
2003-04-28 |
2006-05-16 |
The General Hospital Corporation |
Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
|
US7214491B2
(en)
|
2003-05-07 |
2007-05-08 |
E. I. Du Pont De Nemours And Company |
Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
|
US7589189B2
(en)
|
2003-05-14 |
2009-09-15 |
Japan Science And Technology Agency |
Inhibition of the expression of huntingtin gene
|
CA2524495A1
(en)
*
|
2003-06-03 |
2005-01-13 |
Eli Lilly And Company |
Modulation of survivin expression
|
MXPA05013922A
(es)
|
2003-06-20 |
2006-02-24 |
Coley Pharm Group Inc |
Antagonistas de receptor tipo toll de molecula pequena.
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
JP2011088935A
(ja)
|
2003-08-08 |
2011-05-06 |
Chiralgen Ltd |
リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド3’−ホスホロアミダイト
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
JP2007502779A
(ja)
|
2003-08-21 |
2007-02-15 |
グリフィス ユニバーシティ |
新規スルフェンアミド
|
WO2005019236A1
(en)
|
2003-08-21 |
2005-03-03 |
Griffith University |
Novel sulfenamide oxides
|
JP2007504152A
(ja)
|
2003-08-27 |
2007-03-01 |
ビオタ, インコーポレイテッド |
治療剤としての新規三環ヌクレオシドまたはヌクレオチド
|
ES2382807T3
(es)
|
2003-08-28 |
2012-06-13 |
Takeshi Imanishi |
Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación
|
JP4616175B2
(ja)
|
2003-09-02 |
2011-01-19 |
株式会社キラルジェン |
5’−ホスフィチル化モノマーおよびh−ホスホネートオリゴヌクレオチド誘導体の製造方法
|
JP4580870B2
(ja)
|
2003-09-02 |
2010-11-17 |
株式会社キラルジェン |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
HUE048359T2
(hu)
|
2003-09-09 |
2020-07-28 |
Geron Corp |
Módosított oligonukleotidok telomeráz-gátlásra
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
ES2808561T3
(es)
|
2003-09-12 |
2021-03-01 |
Univ Massachusetts |
Interferencia por ARN para el tratamiento de trastornos de ganancia de función
|
GB0323968D0
(en)
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
NZ546275A
(en)
|
2003-10-30 |
2009-05-31 |
Coley Pharm Gmbh |
C-class oligonucleotides analogs with enhanced immunostimulatory potency
|
WO2005042716A2
(en)
|
2003-10-31 |
2005-05-12 |
President And Fellows Of Harvard College |
Nucleic acid binding oligonucleotides
|
US7846436B2
(en)
*
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
AU2003300239A1
(en)
|
2003-12-29 |
2005-07-21 |
Galapagos Genomics N.V. |
Modulators of bone homeostasis identified in a high-throughput screen
|
WO2005070859A1
(ja)
|
2004-01-27 |
2005-08-04 |
Takeshi Wada |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
US20050176045A1
(en)
|
2004-02-06 |
2005-08-11 |
Dharmacon, Inc. |
SNP discriminatory siRNA
|
US20080221303A1
(en)
|
2004-02-18 |
2008-09-11 |
Jehoshua Katzhendler |
Method for the Preparation of Peptide-Oligonucleotide Conjugates
|
JP3976742B2
(ja)
|
2004-02-27 |
2007-09-19 |
江守商事株式会社 |
インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
WO2005092909A1
(ja)
|
2004-03-25 |
2005-10-06 |
Toudai Tlo, Ltd. |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US20050267300A1
(en)
|
2004-04-05 |
2005-12-01 |
Muthiah Manoharan |
Processes and reagents for oligonucleotide synthesis and purification
|
TWI350168B
(en)
|
2004-05-07 |
2011-10-11 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals
|
AU2005248410B2
(en)
|
2004-05-27 |
2010-04-22 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Differential expression of molecules associated with acute stroke
|
US7759318B1
(en)
|
2004-05-28 |
2010-07-20 |
Isis Pharmaceuticals, Inc. |
Identification of novel pathways, genes and promoter motifs regulating adipogenesis
|
JP2008501694A
(ja)
|
2004-06-03 |
2008-01-24 |
アイシス ファーマシューティカルズ、インク. |
遺伝子調節の使用のために個別に修飾された鎖を有する二本鎖組成物
|
SI2206781T1
(sl)
|
2004-06-28 |
2016-05-31 |
The University Of Western Australia |
Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
|
PL2409713T3
(pl)
|
2004-08-10 |
2016-02-29 |
Kastle Therapeutics Llc |
Oligonukleotydy do zastosowania w modulowaniu poziomów lipoproteiny i cholesterolu u ludzi
|
AU2005275801B2
(en)
|
2004-08-26 |
2012-05-10 |
Nippon Shinyaku Co., Ltd. |
Phosphoramidite compound and method for producing oligo-RNA
|
US20070066551A1
(en)
|
2004-09-07 |
2007-03-22 |
Keefe Anthony D |
Aptamer medicinal chemistry
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006031461A2
(en)
|
2004-09-09 |
2006-03-23 |
Isis Pharmaceuticals, Inc. |
Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
|
WO2006034348A2
(en)
|
2004-09-17 |
2006-03-30 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
EP1807093A2
(en)
|
2004-10-13 |
2007-07-18 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
US8212011B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues
|
WO2006050501A2
(en)
|
2004-11-03 |
2006-05-11 |
University Of Kansas |
Novobiocin analogues as anticancer agents
|
US7622451B2
(en)
|
2004-11-03 |
2009-11-24 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
US8212012B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
KR100721928B1
(ko)
|
2004-11-05 |
2007-05-28 |
주식회사 바이오씨에스 |
CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
|
EP1657307A1
(en)
|
2004-11-16 |
2006-05-17 |
Immunotech S.A. |
Oligonucleotides that induce the secretion of GM-CSF
|
CA2589406A1
(en)
|
2004-12-09 |
2006-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
WO2006066260A2
(en)
|
2004-12-17 |
2006-06-22 |
Thiosense, Inc. |
Compositions of and methods for producing phosphorus-chiral monomers and oligomers
|
US20070099851A1
(en)
|
2004-12-30 |
2007-05-03 |
Linn Gregory S |
Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
|
US20060183763A1
(en)
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
US7902161B2
(en)
|
2005-01-28 |
2011-03-08 |
Hyung-Joo Kwon |
Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
|
EP1851314A2
(en)
|
2005-02-24 |
2007-11-07 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
WO2006137953A1
(en)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
JP4977035B2
(ja)
|
2005-05-05 |
2012-07-18 |
アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
腫瘍の治療における、TGF−β、VEGF、インターロイキン−10、C−JUN、C−FOSまたはプロスタグランジンE2遺伝子にアンチセンスなオリゴヌクレオチドの低適用量の使用
|
US20060257912A1
(en)
|
2005-05-06 |
2006-11-16 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
DK1910395T3
(da)
|
2005-06-23 |
2013-02-04 |
Isis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulation af SMN2-splejsning
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
US20070161590A1
(en)
|
2005-06-28 |
2007-07-12 |
Medtronic, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
US20090162316A1
(en)
|
2005-07-05 |
2009-06-25 |
Harvard University |
Liver targeted conjugates
|
JP4984634B2
(ja)
|
2005-07-21 |
2012-07-25 |
ソニー株式会社 |
物理情報取得方法および物理情報取得装置
|
DK1924252T3
(da)
|
2005-07-28 |
2011-11-14 |
Id Fish Technology Inc |
Fremgangsmåde til forbedring af cellepermeabilitet for fremmede partikler
|
CA2620856C
(en)
|
2005-08-29 |
2017-11-28 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US20070077993A1
(en)
|
2005-09-30 |
2007-04-05 |
Midgley Timothy M |
Method and apparatus for collecting user game play data and crediting users in a gaming environment
|
AU2006304205C1
(en)
|
2005-10-12 |
2012-11-15 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
US9308252B2
(en)
|
2005-10-27 |
2016-04-12 |
Cook Biotech, Inc. |
Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
|
EP1941059A4
(en)
|
2005-10-28 |
2010-11-03 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE HUNTINGTIN GENE
|
CN101466834B
(zh)
|
2005-10-28 |
2013-09-25 |
东曹株式会社 |
制备类胡萝卜素合成性微生物的方法和生产类胡萝卜素的方法
|
US20090082295A1
(en)
|
2005-11-11 |
2009-03-26 |
Pfizer Inc. |
Combinations and methods of using an immunomodulatory oligodeoxynucleotide
|
WO2007064291A1
(en)
|
2005-11-30 |
2007-06-07 |
Jyoti Chattopadhyaya |
Method and compounds for rna synthesis
|
EP1957507B1
(en)
|
2005-12-02 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
|
US8076303B2
(en)
|
2005-12-13 |
2011-12-13 |
Spring Bank Pharmaceuticals, Inc. |
Nucleotide and oligonucleotide prodrugs
|
ES2435405T3
(es)
|
2005-12-21 |
2013-12-19 |
Pfizer Products Inc. |
Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
|
PL3210633T3
(pl)
|
2006-01-26 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i ich zastosowania ukierunkowane na huntingtynę
|
KR20130042043A
(ko)
|
2006-01-27 |
2013-04-25 |
아이시스 파마수티컬즈 인코포레이티드 |
6-변형된 바이시클릭 핵산 유사체
|
DK2405002T3
(en)
|
2006-02-15 |
2015-01-05 |
Adiutide Pharmaceuticals Gmbh |
Compositions and methods for oligonukleotidformuleringer
|
JP4713514B2
(ja)
|
2006-02-20 |
2011-06-29 |
エフ.ホフマン−ラ ロシュ アーゲー |
改善された標識試薬
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
EP2001871B1
(en)
|
2006-03-31 |
2014-07-16 |
Applied Biosystems, LLC |
Rhodamine-labeled oligonucleotides
|
US8088582B2
(en)
|
2006-04-06 |
2012-01-03 |
Ibis Biosciences, Inc. |
Compositions for the use in identification of fungi
|
ATE476424T1
(de)
|
2006-04-20 |
2010-08-15 |
Hoffmann La Roche |
Diazepanderivate als modulatoren von chemokinrezeptoren
|
WO2007123386A1
(es)
|
2006-04-24 |
2007-11-01 |
Sigma Alimentos, S.A. De C.V. |
Método para la detección y cuantificación múltiple y simultánea de patógenos mediante la reacción en cadena de la polimerasa en tiempo real
|
WO2007127219A2
(en)
|
2006-04-25 |
2007-11-08 |
Immune Disease Institute, Inc. |
Targeted delivery to leukocytes using protein carriers
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
EP2023936A4
(en)
|
2006-05-05 |
2010-11-24 |
Isis Pharmaceuticals Inc |
COMPOSITIONS AND THEIR USES ASSOCIATED WITH THE ALPHA PTPR RECEPTOR
|
EP2397551A1
(en)
|
2006-05-05 |
2011-12-21 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PCSK9
|
US20090012120A1
(en)
|
2006-05-10 |
2009-01-08 |
Board Of Trustees Of Michigan State University |
Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
WO2007134181A2
(en)
|
2006-05-11 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
JP5161770B2
(ja)
|
2006-05-31 |
2013-03-13 |
東レ株式会社 |
免疫刺激オリゴヌクレオチド及びその医薬用途
|
US8097596B2
(en)
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
CA2662704A1
(en)
|
2006-07-07 |
2008-01-10 |
University Of Massachusetts |
Rna silencing compositions and methods for the treatment of huntington's disease
|
AU2007272906B2
(en)
|
2006-07-12 |
2013-01-31 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
|
EP2051977A2
(en)
|
2006-07-20 |
2009-04-29 |
Amgen Inc. |
SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
|
GB0614947D0
(en)
|
2006-07-27 |
2006-09-06 |
Isis Innovation |
Epitope reduction therapy
|
WO2008017081A1
(en)
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of jnk proteins
|
AT504194B1
(de)
|
2006-09-07 |
2008-07-15 |
Oesterr Rotes Kreuz |
Bakteriennachweis
|
US8138330B2
(en)
|
2006-09-11 |
2012-03-20 |
Sigma-Aldrich Co. Llc |
Process for the synthesis of oligonucleotides
|
CN101517082B
(zh)
|
2006-09-27 |
2014-01-22 |
科勒制药有限责任公司 |
具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
|
CA2667055C
(en)
|
2006-10-18 |
2017-05-09 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
MX2009004290A
(es)
|
2006-10-23 |
2009-07-27 |
Irm Llc |
Inhibidores de proteasas de catepsina.
|
EP2104738A2
(en)
*
|
2006-10-26 |
2009-09-30 |
Coley Pharmaceuticals GmbH |
Oligoribonucleotides and uses thereof
|
FR2908414B1
(fr)
|
2006-11-13 |
2012-01-20 |
Centre Nat Rech Scient |
Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
|
CA2669917A1
(en)
|
2006-11-17 |
2008-05-22 |
Dawn M. George |
Aminopyrrolidines as chemokine receptor antagonists
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
KR20090103894A
(ko)
|
2006-11-27 |
2009-10-01 |
아이시스 파마수티컬즈 인코포레이티드 |
고콜레스테롤혈증을 치료하는 방법
|
MX2009006230A
(es)
|
2006-12-12 |
2009-06-22 |
Idera Pharmaceuticals Inc |
Agonistas sinteticos de receptores de tipo toll 9.
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
WO2008101157A1
(en)
|
2007-02-15 |
2008-08-21 |
Isis Pharmaceuticals, Inc. |
5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
|
KR20090128494A
(ko)
|
2007-03-24 |
2009-12-15 |
겐자임 코포레이션 |
인간 아포리포프로틴 b에 상보적인 안티센스 올리고뉴클레오타이드 투여
|
US7960353B2
(en)
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
EP3199635B1
(en)
|
2007-05-11 |
2019-02-06 |
Adynxx, Inc. |
Gene expression and pain
|
US8222407B2
(en)
|
2007-05-24 |
2012-07-17 |
Kyorin Pharmaceutical Co., Ltd. |
Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
|
GB0710186D0
(en)
|
2007-05-29 |
2007-07-04 |
Texas Instr Denmark |
PWM loop with minimum allasing error property
|
AU2008260277C1
(en)
|
2007-05-30 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
UA98783C2
(en)
|
2007-06-05 |
2012-06-25 |
Нсаб, Филиал Аф Ньюросерч Свиден Аб, Свериге |
Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
|
ES2386492T3
(es)
|
2007-06-08 |
2012-08-21 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos carbocíclicos
|
EP2164865A2
(en)
|
2007-06-13 |
2010-03-24 |
Hochschule Mannheim |
Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
|
EP2014769B1
(en)
|
2007-06-18 |
2010-03-31 |
Commissariat à l'Energie Atomique |
Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
EP2176280B2
(en)
|
2007-07-05 |
2015-06-24 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
CA2692161C
(en)
|
2007-07-09 |
2015-09-29 |
Idera Pharmaceuticals, Inc. |
Stabilized immune modulatory rna (simra) compounds
|
TWI413530B
(zh)
|
2007-07-20 |
2013-11-01 |
Kao Corp |
有機聚矽氧
|
US8008011B2
(en)
|
2007-07-31 |
2011-08-30 |
University Of Saskatchewan |
Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
|
US7812003B2
(en)
|
2007-08-02 |
2010-10-12 |
Safe Stephen H |
Antisense microRNA and uses therefor
|
AU2008286735A1
(en)
|
2007-08-15 |
2009-02-19 |
Idera Pharmaceuticals, Inc. |
Toll like receptor modulators
|
CN101883777B
(zh)
|
2007-10-01 |
2015-03-25 |
Isis制药公司 |
成纤维细胞生长因子受体4表达的反义调节
|
KR100886139B1
(ko)
|
2007-11-13 |
2009-02-27 |
주식회사 삼천리제약 |
올리고뉴클레오타이드의 제조방법
|
AR069869A1
(es)
|
2007-12-21 |
2010-02-24 |
Exelixis Inc |
Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
|
TWI340765B
(en)
|
2007-12-26 |
2011-04-21 |
Ind Tech Res Inst |
Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
|
WO2009089659A1
(en)
|
2008-01-18 |
2009-07-23 |
Shanghai Targetdrug Co., Ltd. |
Pyrollidine-based compounds
|
JP2011515653A
(ja)
|
2008-02-04 |
2011-05-19 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
神経変性疾患の治療に有用な標的配列及びそれらの同定方法
|
JP2009190983A
(ja)
|
2008-02-12 |
2009-08-27 |
Tokyo Institute Of Technology |
オリゴヌクレオチド誘導体
|
WO2009117589A1
(en)
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
US20110269814A1
(en)
|
2008-03-26 |
2011-11-03 |
Alnylam Pharamaceuticals, Inc. |
2'-f modified rna interference agents
|
EP2271351A4
(en)
|
2008-04-03 |
2016-08-31 |
Spring Bank Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
|
WO2009124238A1
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
EP2262820B1
(de)
|
2008-04-04 |
2013-06-19 |
Universität Hamburg |
Verfahren zur stereoselektiven synthese von phosphorverbindungen
|
US8679750B2
(en)
|
2008-05-09 |
2014-03-25 |
The University Of British Columbia |
Methods and compositions for the treatment of Huntington'S disease
|
WO2009135322A1
(en)
|
2008-05-09 |
2009-11-12 |
The Universtity Of British Columbia |
Methods and compositions for the treatment of huntington's disease
|
AU2009246169B2
(en)
|
2008-05-15 |
2015-01-22 |
Dynavax Technologies Corporation |
Long term disease modification using immunostimulatory oligonucleotides
|
US8541387B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Modulation of SMRT expression
|
US8541388B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of RBP4
|
WO2009143391A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
WO2009148605A2
(en)
|
2008-06-04 |
2009-12-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
WO2010003133A2
(en)
|
2008-07-03 |
2010-01-07 |
Exelixis Inc. |
Cdk modulators
|
WO2010030849A1
(en)
|
2008-09-12 |
2010-03-18 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for treating cancer,inhibiting proliferation, and inducing cell death
|
US8163707B2
(en)
|
2008-09-15 |
2012-04-24 |
Enanta Pharmaceuticals, Inc. |
4′-allene-substituted nucleoside derivatives
|
EP3067359A1
(en)
|
2008-09-23 |
2016-09-14 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
DK2356129T3
(da)
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
US8604192B2
(en)
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
EP2344204A4
(en)
|
2008-10-07 |
2012-07-04 |
Harvard College |
TELOMERASE INHIBITOR AND METHOD OF USE THEREOF
|
JP5592892B2
(ja)
|
2008-10-22 |
2014-09-17 |
クォーク ファーマシューティカルズ インコーポレーティッド |
眼障害の治療方法
|
US20120059045A1
(en)
|
2008-10-24 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
Methods of using oligomeric compounds comprising 2'-substituted nucleosides
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
CN102282155B
(zh)
|
2008-12-02 |
2017-06-09 |
日本波涛生命科学公司 |
磷原子修饰的核酸的合成方法
|
KR20110099333A
(ko)
|
2008-12-23 |
2011-09-07 |
기린두스 아메리카 인코포레이티드 |
황화시약, 및 올리고뉴클레오타이드 합성을 위한 그 용도
|
WO2010080953A1
(en)
|
2009-01-08 |
2010-07-15 |
Isis Pharmaceuticals, Inc. |
Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
|
KR20100087540A
(ko)
|
2009-01-28 |
2010-08-05 |
삼성전자주식회사 |
잉크젯 기록용 잉크 조성물
|
US20120264806A1
(en)
|
2009-02-06 |
2012-10-18 |
Bennett C Frank |
Oligomeric compounds and excipients
|
AU2010213795A1
(en)
|
2009-02-10 |
2011-08-04 |
Idera Pharmaceuticals, Inc. |
Synthetic RNA-based agonists of TLR7
|
JP5766617B2
(ja)
|
2009-02-20 |
2015-08-19 |
ユニバーシティ・オブ・カンザス |
修飾された糖部分を有するノボビオシン類似体
|
EP2669290A1
(en)
|
2009-03-02 |
2013-12-04 |
Alnylam Pharmaceuticals Inc. |
Nucleic Acid Chemical Modifications
|
US9107933B2
(en)
|
2009-03-16 |
2015-08-18 |
Isis Pharmaceuticals, Inc. |
Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
|
WO2010113937A1
(ja)
|
2009-03-31 |
2010-10-07 |
武田薬品工業株式会社 |
ヌクレオシドの製造方法
|
WO2010118263A1
(en)
|
2009-04-08 |
2010-10-14 |
University Of Massachusetts |
Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease
|
CA2759098A1
(en)
|
2009-04-14 |
2010-10-21 |
Smith Holdings, Llc |
Methods and compositions for the treatment of medical conditions involving cellular programming
|
US9260493B2
(en)
|
2009-05-07 |
2016-02-16 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids using modified dsRNA binding domains
|
WO2010141471A2
(en)
|
2009-06-01 |
2010-12-09 |
The Regents Of The University Of California |
Nucleic acid delivery compositions and methods of use thereof
|
PT2437753T
(pt)
|
2009-06-05 |
2016-11-23 |
Infectious Disease Res Inst |
Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
|
JP5707396B2
(ja)
|
2009-06-17 |
2015-04-30 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
被験体におけるsmn2スプライシングのモジュレーションのための組成物および方法
|
JP5670097B2
(ja)
|
2009-06-19 |
2015-02-18 |
花王株式会社 |
二層分離型毛髪化粧料
|
JPWO2010150789A1
(ja)
|
2009-06-23 |
2012-12-10 |
武田薬品工業株式会社 |
核酸の合成法
|
CA2767253A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc. |
Novel nucleic acid prodrugs and methods of use thereof
|
US8329024B2
(en)
|
2009-07-06 |
2012-12-11 |
Ada Technologies, Inc. |
Electrochemical device and method for long-term measurement of hypohalites
|
US8927513B2
(en)
|
2009-07-07 |
2015-01-06 |
Alnylam Pharmaceuticals, Inc. |
5′ phosphate mimics
|
US20110009477A1
(en)
|
2009-07-08 |
2011-01-13 |
Idera Pharmaceuticals, Inc. |
Oligonucleotide-based compounds as inhibitors of toll-like receptors
|
WO2011010706A1
(ja)
|
2009-07-23 |
2011-01-27 |
武田薬品工業株式会社 |
Fgf21シスエレメント結合物質
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
UA107360C2
(en)
|
2009-08-05 |
2014-12-25 |
Biogen Idec Inc |
Bicyclic aryl sphingosine 1-phosphate analogs
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
US8927553B2
(en)
|
2009-08-10 |
2015-01-06 |
Daljit Singh Dhanoa |
Deuterium-enriched alkyl sulfonamides and uses thereof
|
KR102279458B1
(ko)
|
2009-09-11 |
2021-07-21 |
아이오니스 파마수티컬즈, 인코포레이티드 |
헌팅틴 발현의 조절
|
US8470987B2
(en)
|
2009-09-16 |
2013-06-25 |
Chiralgen, Ltd. |
Protective group for synthesis of RNA and derivative
|
US20120270929A1
(en)
|
2009-09-25 |
2012-10-25 |
Isis Pharmaceuticals, Inc. |
Modulation of ttc39 expression to increase hdl
|
AU2010308028A1
(en)
|
2009-10-15 |
2012-04-19 |
Pfizer Inc. |
Pyrrolo[2,3-d] pyrimidine compounds
|
TWI475051B
(zh)
|
2009-11-18 |
2015-03-01 |
Kao Corp |
Organic polysiloxane
|
JP5809408B2
(ja)
|
2009-11-25 |
2015-11-10 |
花王株式会社 |
毛髪化粧料
|
EP2512246B1
(en)
|
2009-12-17 |
2015-09-30 |
Merck Sharp & Dohme Corp. |
Aminopyrimidines as syk inhibitors
|
US8647742B2
(en)
|
2009-12-28 |
2014-02-11 |
Achira Labs Pvt. Ltd. |
Diagnostic gel composition, method for making a diagnostic gel composition
|
CA2786071C
(en)
|
2010-01-08 |
2021-01-12 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
US8750507B2
(en)
|
2010-01-25 |
2014-06-10 |
Cisco Technology, Inc. |
Dynamic group creation for managed key servers
|
US8957040B2
(en)
|
2010-02-08 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
JP6018506B2
(ja)
|
2010-02-08 |
2016-11-02 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
対立遺伝子多様体の選択的低減
|
SG182471A1
(en)
|
2010-02-10 |
2012-08-30 |
Glaxosmithkline Llc |
6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
|
US8859755B2
(en)
|
2010-03-05 |
2014-10-14 |
Chiralgen, Ltd. |
Method for preparing ribonucleoside phosphorothioate
|
WO2011127175A1
(en)
|
2010-04-06 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cd130 (gp130) expression
|
CN102844434A
(zh)
|
2010-04-07 |
2012-12-26 |
Isis制药公司 |
Cetp表达的调节
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
EP2601204B1
(en)
|
2010-04-28 |
2016-09-07 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides and oligomeric compounds prepared therefrom
|
WO2011139699A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
EP2563921B1
(en)
|
2010-04-30 |
2016-11-23 |
Cellectis |
Method for modulating double-strand break-induced homologous recombination
|
GB201008902D0
(en)
|
2010-05-27 |
2010-07-14 |
Imp Innovations Ltd |
Membrane enhanced polymer sythesis
|
ES2908978T3
(es)
|
2010-08-31 |
2022-05-04 |
Sirna Therapeutics Inc |
Nuevas entidades químicas simples y métodos para la administración de oligonucleótidos
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
EP2623600A4
(en)
|
2010-09-30 |
2014-11-26 |
Lsip Llc |
EXPRESSION INHIBITOR OF A DOMINANTLY MUTANT GENE
|
KR101381048B1
(ko)
|
2010-10-20 |
2014-04-14 |
씨제이제일제당 (주) |
O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
JP6093924B2
(ja)
|
2010-11-30 |
2017-03-15 |
株式会社Wave Life Sciences Japan |
2’−o−修飾rna
|
WO2012092367A1
(en)
|
2010-12-28 |
2012-07-05 |
University Of Rochester |
Nucleic acid binding compounds, methods of making, and use thereof
|
EP3467109A1
(en)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
EP2673286B1
(en)
|
2011-02-12 |
2019-07-03 |
University of Iowa Research Foundation |
Therapeutic compounds
|
US9353371B2
(en)
|
2011-05-02 |
2016-05-31 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
AU2012283994A1
(en)
|
2011-07-19 |
2014-03-06 |
University Of Idaho |
Embodiments of a probe and method for targeting nucleic acids
|
CN107365339A
(zh)
|
2011-07-19 |
2017-11-21 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
ES2651514T3
(es)
|
2011-08-11 |
2018-01-26 |
Ionis Pharmaceuticals, Inc. |
Compuestos oligoméricos gapados que comprenden deoxirribonucleósidos modificados en 5 ' -en la brecha y usos de ellos
|
US9976138B2
(en)
|
2011-08-29 |
2018-05-22 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
US20140080896A1
(en)
|
2011-08-30 |
2014-03-20 |
The Regents Of The University Of California |
Identification of small molecules that facilitate therapeutic exon skipping
|
EP3202914B2
(en)
|
2011-08-31 |
2023-06-28 |
The University of Manchester |
Method for treating a neurodegenerative disease
|
US20140255936A1
(en)
|
2011-09-09 |
2014-09-11 |
Mayo Foundation For Medical Education And Research |
Detecting frontotemporal dementia and amyotrophic lateral sclerosis
|
EP3858847A1
(en)
|
2011-11-30 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
KR200460641Y1
(ko)
|
2011-12-07 |
2012-06-04 |
이형호 |
휴대가 용이한 와인 잔
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
IN2014CN04590A
(enrdf_load_html_response)
|
2011-12-16 |
2015-09-18 |
Nat Univ Corp Tokyo Med & Dent |
|
CN102675386B
(zh)
|
2011-12-24 |
2014-07-02 |
河南科技大学 |
一种龙胆苦苷分离提纯方法
|
US8957042B2
(en)
|
2012-03-07 |
2015-02-17 |
The Texas A&M University System |
Cancer treatment targeting non-coding RNA overexpression
|
MD4496C1
(ro)
|
2012-03-13 |
2018-02-28 |
Gilead Sciences, Inc. |
Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
|
KR20130114435A
(ko)
|
2012-04-09 |
2013-10-17 |
삼성전자주식회사 |
다수의 전극을 갖는 생분자 검출 장치
|
HUE033431T2
(en)
|
2012-04-23 |
2017-11-28 |
Biomarin Tech Bv |
RNA modulating oligonucleotides with improved characteristics in the treatment of neuromuscular disorders
|
MX355708B
(es)
|
2012-05-22 |
2018-04-27 |
Idenix Pharmaceuticals Llc |
Compuestos de d-aminoacidos para enfermedades del higado.
|
US9284344B2
(en)
|
2012-05-30 |
2016-03-15 |
Hokkaido System Science Co., Ltd. |
Oligonucleotide synthesis method using highly dispersible liquid-phase support
|
EP2872485B1
(en)
|
2012-07-13 |
2020-12-16 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
CN104661664B
(zh)
|
2012-07-13 |
2020-07-03 |
波涛生命科学有限公司 |
手性控制
|
MX356830B
(es)
|
2012-07-13 |
2018-06-15 |
Shin Nippon Biomedical Laboratories Ltd |
Adyuvante de acido nucleico quiral.
|
DK2879718T3
(da)
|
2012-08-06 |
2023-06-19 |
Alnylam Pharmaceuticals Inc |
Proces til fremstilling af kulhydratkonjugerede RNA-stoffer
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
DK2906256T3
(en)
|
2012-10-12 |
2018-11-19 |
Ionis Pharmaceuticals Inc |
SELECTIVE ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
|
US9963699B2
(en)
|
2012-10-15 |
2018-05-08 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating C9ORF72 expression
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
RU2730677C2
(ru)
|
2012-10-15 |
2020-08-24 |
Ионис Фармасьютикалз, Инк. |
Соединение для модуляции экспрессии гена c9orf72 и его применение
|
EP2725029A1
(en)
|
2012-10-29 |
2014-04-30 |
Laboratoire Biodim |
New antibacterial compounds and biological applications thereof
|
KR20150090894A
(ko)
|
2012-10-29 |
2015-08-06 |
코크리스탈 파마, 아이엔씨. |
바이러스 감염 및 암 치료용 피리미딘 뉴클레오티드 및 그들의 모노포스페이트 프로드럭
|
JP6358955B2
(ja)
|
2012-10-31 |
2018-07-18 |
武田薬品工業株式会社 |
新規修飾核酸
|
BR112015011112A2
(pt)
|
2012-11-15 |
2018-11-06 |
Roche Innovation Center Copenhagen A/S |
composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
|
JP6463687B2
(ja)
|
2012-11-26 |
2019-02-06 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
Fgfr3の発現の調節のための組成物及び方法
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
KR20150110562A
(ko)
|
2013-01-30 |
2015-10-02 |
에프. 호프만-라 로슈 아게 |
Lna 올리고뉴클레오타이드 탄수화물 컨쥬게이트
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
CA2899924A1
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
JP6613143B2
(ja)
|
2013-02-22 |
2019-11-27 |
サーナ・セラピューティクス・インコーポレイテッド |
2’ヌクレオシド間結合を含有する低分子干渉核酸(siNA)分子
|
JP6440170B2
(ja)
|
2013-03-01 |
2018-12-19 |
国立大学法人 東京医科歯科大学 |
キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤
|
CA2907511A1
(en)
|
2013-03-28 |
2014-10-02 |
Syngenta Participations Ag |
Methods of controlling neonicotinoid resistant pests
|
JP2016515552A
(ja)
|
2013-03-28 |
2016-05-30 |
シンジェンタ パーティシペーションズ アーゲー |
ネオニコチノイド耐性有害生物の防除方法
|
CN105378082B
(zh)
|
2013-05-01 |
2020-06-09 |
Ionis制药公司 |
组合物和方法
|
DK3004352T3
(da)
|
2013-05-24 |
2017-11-27 |
Roche Innovation Ct Copenhagen As |
Oligonukleotidmodulatorer af b-celle-cll/lymfom 11a (bcl11a) og anvendelser deraf
|
EP3015467B1
(en)
|
2013-05-24 |
2024-12-04 |
Ajinomoto Co., Inc. |
Morpholino oligonucleotide manufacturing method
|
CN105264073A
(zh)
|
2013-05-30 |
2016-01-20 |
国立大学法人东京医科齿科大学 |
用于递送治疗性寡核苷酸的双链剂
|
CA2915443A1
(en)
|
2013-06-16 |
2014-12-24 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded antisense nucleic acid with exon-skipping effect
|
EP3011028B1
(en)
|
2013-06-21 |
2019-06-12 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
CA2915316C
(en)
|
2013-06-27 |
2024-01-02 |
Roche Innovation Center Copenhagen A/S |
Antisense oligomers and conjugates targeting pcsk9
|
TWI702046B
(zh)
|
2013-07-19 |
2020-08-21 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
JP6697384B2
(ja)
|
2013-07-25 |
2020-05-20 |
イグジキュア, インコーポレーテッドExicure, Inc. |
予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
EP3041833A1
(en)
|
2013-09-06 |
2016-07-13 |
Syngenta Participations AG |
Insecticidal compounds
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
EP3052627B1
(en)
|
2013-10-04 |
2018-08-22 |
Novartis AG |
Novel formats for organic compounds for use in rna interference
|
BR112016007751A2
(pt)
|
2013-10-11 |
2017-09-12 |
Ionis Pharmaceuticals Inc |
composições para modulação de expressão de c9orf72
|
EP3058068B1
(en)
|
2013-10-14 |
2019-04-24 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
EP3058069B1
(en)
|
2013-10-14 |
2019-07-24 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating expression of c9orf72 antisense transcript
|
NZ719477A
(en)
|
2013-11-11 |
2022-05-27 |
Sangamo Therapeutics Inc |
Methods and compositions for treating huntington’s disease
|
WO2015071388A1
(en)
|
2013-11-14 |
2015-05-21 |
Roche Innovation Center Copenhagen A/S |
Apob antisense conjugate compounds
|
EP2918275B1
(en)
|
2013-12-13 |
2016-05-18 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
EP3095459A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
EP4137572A1
(en)
|
2014-01-16 |
2023-02-22 |
Wave Life Sciences Ltd. |
Chiral design
|
ES2856403T3
(es)
|
2014-03-18 |
2021-09-27 |
Univ Massachusetts |
Composiciones a base de rAAV y procedimientos para el tratamiento de la esclerosis lateral amiotrofica
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
MX382230B
(es)
|
2014-05-01 |
2025-03-13 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
|
KR102380324B1
(ko)
|
2014-05-08 |
2022-03-30 |
상가모 테라퓨틱스, 인코포레이티드 |
헌팅턴병을 치료하기 위한 방법 및 조성물
|
CA2949437C
(en)
|
2014-05-20 |
2023-08-15 |
University Of Iowa Research Foundation |
Huntington's disease therapeutic compounds
|
US20160017327A1
(en)
|
2014-07-11 |
2016-01-21 |
The Johns Hopkins University |
Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
|
WO2016011226A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP2982758A1
(en)
|
2014-08-04 |
2016-02-10 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Genome editing for the treatment of huntington's disease
|
CA2956554C
(en)
|
2014-08-07 |
2022-03-01 |
Takeda Pharmaceutical Company Limited |
Preparation of cationic lipid compounds and their salts as nucleic acid carriers
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
WO2016037191A1
(en)
|
2014-09-05 |
2016-03-10 |
Health Research, Inc. |
Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
JP2017536119A
(ja)
|
2014-11-19 |
2017-12-07 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド
|
US10815481B2
(en)
|
2014-12-16 |
2020-10-27 |
Roche Innovation Center Copenhagen A/S |
Chiral library screen
|
AU2015370903B2
(en)
|
2014-12-24 |
2021-06-17 |
Uniqure Ip B.V. |
RNAi induced huntingtin gene suppression
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
US20180023081A1
(en)
|
2015-02-04 |
2018-01-25 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
JP6772156B2
(ja)
|
2015-02-04 |
2020-10-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
治療用分子を選択する方法
|
KR20180016970A
(ko)
|
2015-02-04 |
2018-02-20 |
에프. 호프만-라 로슈 아게 |
타우 안티센스 올리고머와 그 용도
|
CR20170406A
(es)
|
2015-02-10 |
2017-11-14 |
Genzyme Corp |
Arni variante
|
AU2016219263B2
(en)
|
2015-02-13 |
2022-12-01 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
|
US10370659B2
(en)
|
2015-02-23 |
2019-08-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing antisense activity
|
WO2016141236A1
(en)
|
2015-03-03 |
2016-09-09 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
WO2016145142A1
(en)
|
2015-03-10 |
2016-09-15 |
Emory University |
Nucleotide and nucleoside therapeutics compositions and uses related thereto
|
WO2016154096A1
(en)
|
2015-03-20 |
2016-09-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of smggds expression
|
US9809817B2
(en)
|
2015-04-03 |
2017-11-07 |
University Of Massachusetts |
Oligonucleotide compounds for targeting huntingtin mRNA
|
WO2016164896A2
(en)
|
2015-04-10 |
2016-10-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of smn expression
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
SG11201708468YA
(en)
|
2015-04-16 |
2017-11-29 |
Ionis Pharmaceuticals Inc |
Compositions for modulating c9orf72 expression
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
EP3313989B1
(en)
|
2015-06-29 |
2024-12-25 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
CN109477106B
(zh)
|
2015-07-10 |
2022-10-04 |
Ionis制药公司 |
二酰基甘油酰基转移酶2(dgat2)的调节剂
|
EP3324980B1
(en)
|
2015-07-17 |
2021-11-10 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
TW201718620A
(zh)
|
2015-07-27 |
2017-06-01 |
阿尼拉製藥公司 |
黃嘌呤脫氫酶(XDH)iRNA組成物及其使用方法
|
LT3329002T
(lt)
|
2015-07-31 |
2021-01-11 |
Alnylam Pharmaceuticals, Inc. |
Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
|
DK3341479T3
(da)
|
2015-08-24 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
LNA-G-Proces
|
EA201890571A1
(ru)
|
2015-08-25 |
2018-10-31 |
Элнилэм Фармасьютикалз, Инк. |
Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
US20180273573A1
(en)
|
2015-10-01 |
2018-09-27 |
Memorial Sloan-Kettering Cancer Center |
Inhibitors of menaquinone biosynthesis
|
US10874686B2
(en)
|
2015-10-01 |
2020-12-29 |
Memorial Sloan-Kettering Cancer Center |
Anthranilyl-adenosinemonosulfamate analogs and uses thereof
|
US10577388B2
(en)
|
2015-10-02 |
2020-03-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
TW201722439A
(zh)
|
2015-10-09 |
2017-07-01 |
波濤生命科學有限公司 |
寡核苷酸組合物及其方法
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
WO2017079291A1
(en)
|
2015-11-02 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating c90rf72
|
RS61529B9
(sr)
|
2015-11-12 |
2024-04-30 |
Hoffmann La Roche |
Oligonukleotidi za indukovanje ekspresije paternalnog ube3a
|
WO2017160741A1
(en)
|
2016-03-13 |
2017-09-21 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
CN108779465B
(zh)
|
2016-03-14 |
2022-05-13 |
豪夫迈·罗氏有限公司 |
用于减少pd-l1表达的寡核苷酸
|
US11267843B2
(en)
|
2016-03-18 |
2022-03-08 |
Roche Innovation Center Copenhagen A/S |
Stereodefining L-monomers
|
US11963972B2
(en)
|
2016-03-23 |
2024-04-23 |
Emory University |
Antiviral agents and nucleoside analogs for treatment of Zika virus
|
EP3443094B1
(en)
|
2016-04-13 |
2022-10-19 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
US11261209B2
(en)
|
2016-05-12 |
2022-03-01 |
Roche Innovation Center Copenhagen A/S |
Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
|
CA3023621C
(en)
|
2016-05-13 |
2021-07-27 |
F. Hoffmann-La Roche Ag |
Protein-based sample collection matrices and devices
|
US10882884B2
(en)
|
2016-05-18 |
2021-01-05 |
Eth Zurich |
Stereoselective synthesis of phosphorothioate oligoribonucleotides
|
EP3463386A4
(en)
|
2016-06-03 |
2020-03-04 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDES, COMPOSITIONS AND ASSOCIATED METHODS
|
CN109310765A
(zh)
|
2016-06-20 |
2019-02-05 |
领先基因生物技术股份有限公司 |
抗体-药物偶联物
|
US20190264267A1
(en)
|
2016-07-25 |
2019-08-29 |
Wave Life Sciences Ltd. |
Phasing
|
US11873316B2
(en)
|
2016-11-23 |
2024-01-16 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|